---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-25-000087"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:16:38.020688+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agios Q2 2025 net loss $112M; PYRUKYND revenue $12.5M; PDUFA Sept 7 for thalassemia

## Summary
- Net loss $112.0M vs $96.1M YoY; PYRUKYND net revenue $12.5M, up from $8.6M in Q2 2024.
- Cash and marketable securities $1.3B; expects to fund potential thalassemia and SCD launches.
- FDA PDUFA goal date for PYRUKYND sNDA in thalassemia is Sept 7, 2025; launch prep underway.
- RISE UP Phase 3 topline for mitapivat in sickle cell disease on track by year-end 2025.
- Dosed first patient in tebapivat Phase 2 for SCD; IND clearance for AG-236 siRNA for PV.

## SEC filing metadata
- accession: 0001439222-25-000087
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/0001439222-25-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-25-000087
- JSON: https://secwatch.observer/filing/0001439222-25-000087.json
- Plain text: https://secwatch.observer/filing/0001439222-25-000087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.